Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients

Immune checkpoint inhibitors (ICIs) including anti-PD-1 and anti-PD-L1 antibodies, have significantly changed the treatment outcomes of NSCLC patients with better overall survival. However, 15-40% of the patients still fail to respond to ICIs therapy. Identification of biomarkers associated with res...

Descripción completa

Detalles Bibliográficos
Autores principales: Akbar, Shayista, Raza, Afsheen, Mohsin, Reyad, Kanbour, Aladdin, Qadri, Shahnaz, Parray, Aijaz, Zar Gul, Abdul Rehman, Philip, Anite, Vijayakumar, Suma, Merhi, Maysaloun, Hydrose, Shereena, Inchakalody, Varghese Philipose, Al-Abdulla, Rajaa, Abualainin, Wafa, Sirriya, Shaza Abu, Al-Bozom, Issam, Uddin, Shahab, Khan, Omar Muhammad, Mohamed Ibrahim, Mohamed Izham, Al Homsi, Ussama, Dermime, Said
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890181/
https://www.ncbi.nlm.nih.gov/pubmed/36741391
http://dx.doi.org/10.3389/fimmu.2022.1097117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890181/
https://www.ncbi.nlm.nih.gov/pubmed/36741391
http://dx.doi.org/10.3389/fimmu.2022.1097117

Ejemplares similares